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The interleukin (IL)-12 family, which is composed of heterodimeric cytokines including IL-12, IL-23, and IL-27, is produced by
antigen-presenting cells such as macrophages and dendritic cells and plays critical roles in the regulation of helper T (Th) cell
diﬀerentiation. IL-12 induces IFN-γ production by NK and T cells and diﬀerentiation to Th1 cells. IL-23 induces IL-17 production
bymemoryTcellsandexpandsandmaintainsinﬂammatoryTh17cells.IL-27inducestheearlyTh1diﬀerentiationandgeneration
of IL-10-producing regulatory T cells. In addition, these cytokines induce distinct immune responses to tumors. IL-12 activates
signal transducers and activator of transcription (STAT)4 and enhances antitumor cellular immunity through interferon (IFN)-γ
production. IL-27 activates STAT1, as does IFN-γ and STAT3 as well, and enhances antitumor immunity by augmenting cellular
and humoral immunities. In contrast, although exogenously overexpressed IL-23 enhances antitumor immunity via memory T
cells, endogenous IL-23 promotes protumor immunity through STAT3 activation by inducing inﬂammatory responses including
IL-17 production.
1.Introduction
1.1. Cytokine-Based Cancer Immunotherapy. Tumor cells are
characterized by low expression of major histocompatibility
complex (MHC) class and costimulatory molecules such
as CD80 and CD86. In mice bearing tumors and cancer
patients, the production of immune suppressive cytokines
such as interleukin (IL)-10 and transforming growth factor
(TGF)-β is accelerated, and immune regulatory cells such
as regulatory T (Treg) cells and IL-10-producing type I
Treg (Tr1) cells are highly inﬁltrated in tumor microenvi-
ronment. Thus, tumor cells can escape from the immune
surveillance system. As one of the strategies to enhance
the antitumor immune responses, it is possible to activate
tumor-speciﬁc antitumor immune responses by systemic
injection of cytokine or introduction of cytokine gene into
tumors through activating natural killer (NK) cells and
tumor-speciﬁc CD4+ Tc e l l sa n dc y t o t o x i cTl y m p h o c y t e s
(CTL). In order to localize the eﬀect of cytokine within
tumor microenvironment, tumor cells are transfected with
cytokine gene and then injected into host. These tumors
begin to grow but then regress and are ﬁnally rejected.
In some cases, intense inﬂammatory inﬁltrates accumulate
around the cytokine-secreting tumors, and the nature of
the inﬁltrate varies with the cytokine. Diﬀerent cytokines
may stimulate antitumor immune responses by diﬀerent
mechanisms.Importantly,theinjectionofcytokine-secreting
tumors induces T-cell-mediated immunity speciﬁc to the
parental tumor cells.
1.2. Cancer Immunotherapy Using Granulocyte Macrophage
Colony-StimulatingFactor(GM-CSF)andIL-2. Forinstance,
GM-CSF, which acts on bone marrow cells and diﬀerentiates
and matures them to neutrophils, monocytes, and dendritic
cells (DCs), is used to generate the cancer immunotherapy2 Clinical and Developmental Immunology
called GAVX [1, 2]. The tumor cells, transfected with
GM-CSF gene, have been demonstrated to induce potent,
long-lasting, tolerance-breaking, and tumoricidal immune
responses in a variety of tumor models including poorly
immunogenic tumors. In clinical trials using the GAVX,
induction of systemic antitumor immune responses and
clinical activity was observed in renal cell carcinoma,
melanoma,pancreaticcancer,andprostatecancer.Moreover,
IL-2 is a growth factor for T lymphocytes and NK cells. In
the beginning of 1980s, lymphokine-activated killer (LAK)
therapy was developed by Rosenberg and his colleagues [3],
and high-dose bolus schedules of IL-2 showed promising
eﬀects in metastatic renal cell carcinoma with LAK cells
or tumor inﬁltrating lymphocytes [4]. Subsequently, the
administration of high-dose bolus IL-2 has consistently
induced durable responses in a small percentage of patients
with advanced renal cell carcinoma [5].
1.3. Cancer Immunotherapy Using Novel Cytokines. Cancer
immunotherapy has thus the potential of being the most
tumor-speciﬁc treatment that can be devised. More recently,
several exciting cytokines have been characterized that have
considerable promise for future cancer immunotherapy. The
identiﬁcation of new cytokines will open up a novel avenue
to develop the cancer immunotherapy. So far, cytokines
up to IL-35 have been identiﬁed. Among them, the IL-
12 family cytokines have quite unique properties that they
are heterodimeric cytokines and produced by antigen-
presenting cells such as macrophages and DCs, and play
criticalrolesintheregulationofhelperT(Th)diﬀerentiation
(Figure 1)[ 6]. Although IL-12 is one of the most powerful
antitumor cytokine [7, 8], accumulating evidence revealed
that the individual members of the IL-12 family play distinct
roles in the regulation of antitumor immune responses.
1.4. Regulation of Antitumor Immune Responses by Inﬂam-
mation. While immune surveillance thus induces antitumor
immune responses, chronic inﬂammation has long been
considered to be associated with increased incidence of
malignancy [9]. Recently, substantial numbers of evidence
indicate that immune system also promotes the tumorigene-
sis, invasion, propagation, and metastasis of tumors [10, 11].
Moreover,inﬁltrationofeﬀectorcellssuchasCTLsintumors
generally results in good prognosis, while inﬁltration of
macrophages often leads to bad prognosis. More recently,
the molecular mechanism whereby the inﬂammation regu-
lates the antitumor immune responses has been elucidated
[12]. In many tumors, signal transducers and activator of
transcription (STAT)3 are activated [13], and thereby IL-12
production is inhibited, and antitumor immune surveillance
is suppressed. On the contrary, the production of IL-23,
which plays critical roles in expansion and maintenance
of Th17 cells producing inﬂammatory IL-17, is augmented
through STAT3 activation, resulting in inﬂammation, which
is advantageous in the promotion of tumorigenesis.
In the present paper, we summarize the recent advance
on the regulation of antitumor immune responses by the IL-
12 family cytokines, IL-12, IL-23, and IL-27.
2.IL-12
2.1. Molecular Characterization of IL-12. IL-12 was indepen-
dently identiﬁed as natural killer-stimulating factor (NKSF)
and cytotoxic lymphocyte maturation factor (CLMF) by
Trinchieri’s group in 1989 [14] and Gately’s group in 1990
[15],respectively.ItscDNAwasthenclonedin1991[16]and
named IL-12. IL-12, which consists of p40 and p35 subunits,
induces proliferation of NK and T cells and production of
cytokines,especiallyIFN-γ,andalsoenhancesthegeneration
and activity of CTLs, through activation of STAT4 [17,
18]. IL-12 is an essential cytokine for the diﬀerentiation
to Th1 cells, which is required for the generation of type
1 cell-mediated immunity to cancer and infection. IFN-γ,
produced by IL-12, then upregulates the expression of MHC
class I and II molecules, adhesion molecules such as intracel-
lularadhesionmolecules(ICAM)-1andtranscriptionfactors
such as T-box expressed in T cells (T-bet). IL-12 also induces
the productionof antiangiogenic chemokines suchas IFN-γ-
inducible protein (IP-10, CXCL10) and monokine-induced
by IFN-γ (MIG, CXCL9) in endothelial cells [8]. Of note,
the endogenous production of IFN-γ is required for the
antitumor eﬀect of IL-12 in most, if not all, cases [19–21].
2.2. Potent Antitumor Activity of IL-12. The antitumor
and antimetastatic activities of IL-12 have been extensively
examined in a variety of murine tumor models including
melanomas, mammary carcinomas, colon carcinoma, renal
carcinoma,and sarcomas[7, 8].For instance,administration
of IL-12 into tumor-bearing mice can delay, reduce, and,
in some cases, completely inhibit tumor development with
signiﬁcant therapeutic eﬃcacy in many solid tumors as
well as hematological leukemias and lymphomas. In clinical
trials, however, the therapeutic eﬀect has been limited by
low eﬃcacy and systemic toxicities such as splenomegaly,
leucopenia, and gastrointestinal toxicity [21–23]. Although
the reasons for the limited clinical eﬃcacy of IL-12 in
cancer patients remain incompletely understood, several
immunosuppressive mechanisms including a Th1 to Th2
shift due to increased IL-10 production and diminished
IFN-γ production after repetitive treatments with IL-12
could be involved [24, 25]. In addition, immune suppressive
microenvironment characterized by inﬁltration of Treg cells
and Tr1 cells in advanced tumors [26]c o u l dc o n t r i b u t e
to the limited eﬃcacy. To improve the therapeutic eﬃcacy
with IL-12 but simultaneously minimize the toxicity, several
strategies have been created including targeting of IL-12 to
only tumor, and coadministration with Treg cell-depleting
antibodies such as anti-CD25 antibody, antibodies against
immune suppressive signals such as cytotoxic T lymphocyte
antigen(CTLA)-4andIL-10,othercytokines,andanticancer
drugs. Thus, IL-12 is one of the most potential cytokine for
cancer immunotherapy.
3.IL-27
3.1. Molecular Characterization of IL-27. IL-27, which has
structurally and functionally similarities to IL-12, was
identiﬁed by Kastelein’s group in 2002 [27]. IL-27, whichClinical and Developmental Immunology 3
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Figure 1: Molecular characterization of the IL-12 family cytokines, IL-12, IL-23, IL-27, and IL-35. IL-12 induces IFN-γ production by NK
and T cells and diﬀerentiation to Th1 cells. IL-23 induces IL-17 production by memory T cells and expands and maintains inﬂammatory
Th17 cells. IL-27 induces the early Th1 diﬀerentiation and generation of IL-10-producing Tr1 cells. In addition, these cytokines induce
distinct immune responses to tumors. IL-12 activates STAT4 and enhances antitumor cellular immunity through IFN-γ production. IL-27
a c t i v a t e sS T A T 1 ,a sd o e sI F N - γ and STAT3 as well, and enhances antitumor immunity by augmenting cellular and humoral immunities.
In contrast, although exogenously overexpressed IL-23 enhances antitumor immunity via memory T cells, endogenous IL-23 promotes
protumor immunity through STAT3 activation by inducing inﬂammatory responses including IL-17 production.
consists of EBI3 subunit and the IL-12p35 subunit, activates
both STAT1 and STAT3 through distinct IL-27 receptor
(R) subunits, WSX-1 and gp130, respectively, and enhances
proliferation of naive CD4+T cells [27–30]. IL-27 promotes
the early Th1 diﬀerentiation through upregulation of ICAM-
1[ 30]a n dT - b e t[ 28], but it suppresses the diﬀerentiation
to Th2 [31, 32]a n dT h 1 7[ 33, 34] and production of
pro-inﬂammatory cytokines [35, 36]. One possible mech-
anism for the suppressive function is considered to be
mediated through IL-10 production [37–39]. In addition,
IL-27 plays a dominant function together with TGF-β
in generating IL-10-producing anti-inﬂammatory Tr1 cells
[40].
3.2. Antitumor Activity of IL-27 Mediated by CD8+ TC e l l s .
Since Hisada et al. ﬁrst evaluated the antitumor eﬃcacy of
IL-27 in 2004 [41], accumulating evidence has revealed that
IL-27 has a potent antitumor activity, which is mediated by
a variety of mechanisms including CD8+T cells [41–45], NK
cells[46–48],antibody-dependentcell-mediatedcytotoxicity
(ADCC) [49], antiangiogenesis [50], direct suppression of
tumor growth [51], and inhibition of cychroxygenase-2
(COX-2)expression[52],dependingonthecharacteristicsof
individual tumors (Figure 2). Because each subunit of IL-27
is not chemically bound like IL-12 and IL-23, a single chain
expression vector was constructed using ﬂexible linker such
as (Gly4Ser)3 and resultant recombinant fusion protein was
prepared [27, 41]. For instance, highly immunogenic murine
colon carcinoma Colon 26 cells transfected with the IL-27
expression vector showed greatly reduced tumor growth,
which is mainly mediated by CD8+ T cells, IFN-γ and T-bet
[41].InadditiontoCD4+ Tcells,IL-27directlyactsonCD8+
T cells to induce the expression of transcriptional factors,
T-bet and Eomesodermin (EOMES) and thereby augments
the generation of CTL through enhancing the expression of
eﬀector molecules such as granzyme B and perforin [53].
In addition, IL-27 has an adjuvant activity for induction of
epitope-speciﬁc CTL in a prime-boost immunization [54].4 Clinical and Developmental Immunology
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Figure 2: Diﬀerences in the molecular mechanisms to induce antitumor eﬀects between IL-12 and IL-27. IL-27 utilizes several mechanisms
to induce antitumor eﬀects depending on characteristics of individual tumors. Against highly immunogenic tumors expressing MHC class
I, IL-27 exerts antitumor eﬀects by mainly CD8+ T cells. However, against poorly immunogenic tumors lacking expression of IL-27R, IL-27
has to use other mechanisms including NK cells and antiangiogenesis to exert its antitumor eﬀects. In contrast, IL-12 has a strong antitumor
eﬀect through high production of IFN-γ by NK and T cells. This high IFN-γ production also causes systemic toxicities, which leads to
limitation of the IL-12 therapy in clinical trials.
The role of endogenous IL-27 in the generation of CTL and
antitumor immunity was also examined using mice deﬁcient
in WSX-1, one of the IL-27R subunits [55]. Endogenous IL-
27 was revealed to promote tumor-speciﬁc CTL generation
in CD8+ T cells, while suppressing APC function in DCs,
during generation of tumor immunity. Thus, IL-27 plays an
important role in the induction of CTL [56].
3.3. Antitumor Activity of IL-27 Mediated by NK Cells,
Angiogenesis,andIts DirectEﬀects onTumors. The antitumor
eﬀects of IL-27 against poorly immunogenic tumors such
as B16F10 melanoma are mediated by various mechanisms
through NK cells [46–48], angiogenesis [50], and its direct
eﬀects on tumors [51, 52]. IL-27 not only activates NK
cells but also induces tumor-speciﬁc immunoglobulin that
cooperatively elicit ADCC activity [49]. IL-27 also possesses
potent antiangiogenic activity on melanomas as does IFN-
γ, which contributes to its antitumor and antimetastatic
activities [50]. B16F10 cells transfected with IL-27 gene
exert antitumor activity against subcutaneous tumor and
also experimental pulmonary metastasis even in IFN-γ-
deﬁcient mice. Moreover, in immunodeﬁcient NOD-SCID
micelackingafunctionalimmunesystemincludingT,B,and
NK cells, the antitumor activities are decreased, but they are
still fairly well retained by exogenous expression of IL-27,
suggestingthatdiﬀerentmechanismsotherthantheimmune
response are also involved. B16F10 cells transfected with IL-
27 gene not only markedly suppress tumor-induced neovas-
cularization in lung metastases but also clearly inhibit angio-
genesis. Consistent with these results, IL-27 was revealed
to directly act on human umbilical vein endothelial cells
and induce production of the antiangiogenic chemokines
such as IP-10 and MIG. IL-27 also possesses potent direct
antiproliferative activity on melanomas as does IFN-γ [51].
Although parental B16F10 cells express only gp130 but
not WSX-1 IL-27 induces activation of STAT1 and STAT3
and upregulation of MHC class I in B16F10 transfectants
expressingwild-typeWSX-1,andinhibitsthegrowthoftheseClinical and Developmental Immunology 5
tumors as well. Moreover, IL-27 induces the expression of
both IFN-regulatory factor (IRF)-1 and -8 whereas IRF-1
but not IRF-8 is partially involved in these eﬀects. Similar
direct antiproliferative eﬀect is observed in several human
melanomas.
3.4. Diﬀerences in the Molecular Mechanisms to Induce Anti-
tumor Eﬀects between IL-12 and IL-27. As mentioned above,
IL-27utilizesseveralmechanismstoinduceantitumoreﬀects
depending on characteristics of individual tumors. Against
highly immunogenic tumors expressing MHC class I, IL-27
exerts antitumor eﬀects by mainly CD8+ T cells. However,
against poorly immunogenic tumors lacking expression of
IL-27R, IL-27 cannot induce antitumor eﬀect by CD8+ T
cells. This is because IL-27 itself has only weak ability to
induce IFN-γ production and therefore fails to upregulate
MHC class I expression on these tumors. Thus, IL-27 has
to use other mechanisms including NK cells and antiangio-
genesis to exert its antitumor eﬀects. In contrast, IL-12 has
a strong antitumor eﬀect through high production of IFN-γ
by NK and T cells [7, 8]. This high IFN-γ production also
causes systemic toxicities, which leads to limitation of the
IL-12 therapy in clinical trials [21–23]. In this regards, since
IL-27 has much less toxicities compared with IL-12 [41, 46],
probably due to much lower ability of IL-27 to produce IFN-
γ by NK cells, IL-27 may be an attractive candidate as an
antitumor agent applicable to cancer immunotherapy.
4.IL-23
4.1.MolecularCharacterizationofIL-23. IL-23wasidentiﬁed
by Kastelein’s group in 2000 and is composed of the IL-
23-speciﬁc p19 subunit and the IL-12p40 subunit [57].
IL-23 activates STAT3 and preferentially acts on memory
CD4+T cells and induces their proliferation and production
of cytokines such as IL-17 and IL-22 [58, 59]. Although
p19-deﬁcient mice are highly resistant to the development
of experimental allergic encephalomyelitis (EAE) [60], the
physiological roles of IL-23 is considered to only expand and
maintain the inﬂammatory Th17 cells [61], and TGF-β and
IL-6arenecessarytoinducetheTh17diﬀerentiation[62,63].
4.2. Antitumor Eﬀect of Exogenously Overexpressed IL-23.
Murine colon carcinoma CT26 and B16F10 tumor cells
transfected with IL-23 gene show potent antitumor and
antimetastatic eﬀects similar to those of IL-12 [46, 64, 65].
However, the antitumor mechanisms induced by IL-12 and
IL-23 are quite diﬀerent. IL-23-mediated tumor suppression
is only evident at later time points after tumor inoculation,
while IL-12-induced tumor suppression is obvious in an
earlier time points [46, 64]. Since the protective eﬀects
of IL-23 are completely abrogated in mice depleted of
CD8+ T cells, CD8+ T cells play an important role in the
IL-23-mediated antitumor activity. Moreover, when high-
dose IL-23 is systemically administrated into the pretibial
muscles using in vivo electroporation of IL-23 plasmid,
signiﬁcant suppression of the growth of preexisting MCA205
ﬁbrosarcoma and prolongation of the survival without any
signiﬁcant toxicity are observed [66]. For these potent
antitumor eﬀects of IL-23 treatment, fully promoted Th1-
type response in the presence of endogenously expressed
IL-12 is necessary. Thus, exogenously overexpressed IL-23
in tumor cells induces a potent antitumor eﬀect through
memory T cells.
4.3. Protumor Eﬀect of Endogenous IL-23. Contrary to the
exogenous IL-23, endogenous expression of IL-23 has been
reported to promote tumor incidence and growth, and
there are strikingly diﬀerences in the regulation of immune
surveillance to tumors between IL-12- and IL-23-deﬁcient
mice (Figure 3)[ 10, 11]. IL-12 deﬁciency increases not only
the incidence of tumors but also allows for rapid tumor
growth in mice. By contrast, deﬁciency in IL-23 or the
IL-23R not only dramatically reduces tumor incidence but
also reduces tumor growth of established tumors [10]. In
the local tumor microenvironment, IL-23 not only induces
the hallmarks of chronic inﬂammation such as matrix
metalloproteases (MMPs), angiogenesis, and macrophage
inﬁltration, but also reduces antitumor immune surveillance
by locally suppressing the presence of CD8+ T cells [10].
By contrast, the absence of IL-12 leads to exacerbation of
the myeloid-driven inﬂammation with a coincident lack of
CD8+ T cells. Of note, IL-23p19 and IL-12p40, but not IL-
12p35, are overexpressed in the majority of human cancers.
Taken together, endogenous IL-23 expression promotes
tumor incidence and growth, while application of IL-23 at
the excessive amount induces antitumor immune responses
with the characteristics immune responses mediated by the
function of CD4+ and CD8+ T cells.
4.4. Promotion of Tumorigenesis by STAT3 Activation. The
transcription factor STAT3 is constitutively activated in
diverse cancers [13]. Its activation favors proliferation of
tumor cells by exerting an antiapoptotic eﬀect, in part,
mediated by transcriptional downregulation of p53 and
by inducing factors that drive angiogenesis and metastasis
including vascular endothelial growth factor (VEGF) and
MMPs [67]. Several immunosuppressive factors including
IL-10 are also produced. Although STAT3 activation induces
recruitment of hematopoietic cells, STAT3 activation in
tumor-associated macrophages (TAMs) and DCs has a
profoundanti-inﬂammatoryeﬀectbypreventingtheirmatu-
ration andblocking theirability toproducemanyproinﬂam-
matory cytokines such as IL-12 (Figure 3)[ 12, 68]. Indeed,
progressing tumors in humans and experimental animals
are characterized by the presence of inﬁltrating immature
and anergic TAMs and DCs and a limited inﬁltration of T
lymphocytes that often have the characteristic of Treg cells.
Treg cells play a role in inactivation of antigen-presenting
cells and suppression of proliferation and antitumor activity
of eﬀector T cells, including IFN-γ-producing Th1 cells and
CTLswithantitumoractivity,bytheproductionofIL-10and
TGF-β or direct cellular contacts [69].
4.5. Promotion of IL-23-Mediated Protumor Immune
Responses by STAT3 while Inhibiting IL-12-Dependent6 Clinical and Developmental Immunology
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Figure 3: Diﬀerences in the immune responses to tumor induced by IL-12 and IL-23 and their molecular mechanisms in tumor
microenvironments. STAT3 activation induces IL-23 expression, which is mainly observed in TAMs, via direct transcriptional activation
of the IL-23p19 gene together with NF-κB/RelA(p65). On the other hand, STAT3 activation inhibits NF-κB/c-Rel-dependent IL-12p35 gene
expression in tumor-associated DCs, possibly through the STAT3-dependent induction of the ETS transcriptional suppressor ETV3 and the
helicase family corepressor SBNO2. Thus, STAT3 promotes IL-23-mediated protumor immune responses while inhibiting IL-12-dependent
antitumor immunity.
Antitumor Immune Responses. Interactions between tumor
and immune cells either enhance or inhibit cancer
progression. STAT3 signaling within the tumor microenvi-
ronment was recently elucidated to induce a protumor
cytokine, IL-23, while inhibiting a central antitumor
cytokine, IL-12, thereby shifting the balance of tumor
immunity toward tumorigenesis (Figure 3)[ 12, 68]. STAT3
activation induces IL-23 expression, which is mainly
observed in TAMs, via direct transcriptional activation of
the IL-23p19 gene together with NF-κB/RelA(p65). On
the other hand, STAT3 activation inhibits NF-κB/c-Rel-
dependent IL-12p35 gene expression in tumor-associated
DCs, possibly through the STAT3-dependent induction
of the ETS transcriptional suppressor, ETS variant gene
3 (ETV3), and the helicase family corepressor, strawberry
notch homolog 2 (SBNO2). These transcription factors
were previously demonstrated to mediate the inhibition
of gene transcription by IL-10-induced STAT3 activation
[70]. Interestingly, unlike spleen Treg cells, tumor-associated
Treg cells express IL-23R and activates STAT3 in response
to IL-23, leading to upregulation of the Treg-speciﬁc
transcription factor Foxp3 and the immunosuppressive
cytokine IL-10. This is surprising because in other settings,
S T A T 3a c t i v a t i o nb yI L - 6o rI L - 2 1i nT G F - β-exposed T
cells induces downregulation of Foxp3 and upregulation
of the transcription factor RORγt leading to induction of
IL-17-producing Th17 cells [71]. These results demonstrate
that STAT3 promotes IL-23-mediated protumor immune
responses while inhibiting IL-12-dependent antitumor
immunity.
5. Conclusion
Recently,anothernovel cytokine, IL-35,whichbelongstothe
IL-12 family, was identiﬁed by Vignali’s group in 2007 [72].
IL-35 consists of the IL-27 EBI3 subunit and the IL-12p35Clinical and Developmental Immunology 7
subunit, produced by Treg cells, but not eﬀector T cells, after
interaction between Treg and eﬀector T cells, and it plays
a role in immune suppression. However, the role of IL-35
in the regulation of immune responses in various diseases
including cancer and infection remains largely unknown
[73]. Collectively, IL-12, IL-23, IL-27, and probably IL-35,
which belong to the same IL-12 family, play critical roles
in the regulation of antitumor and/or protumor immune
responses in respective situation.
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